Stevanato Group S.p.A. (STVN) — 分析摘要
Stevanato Group S.p.A.（STVN）的市值为6.09十亿美元，最近一年的营收同比增长了+12.5%。净利润率为11.8%。当前市盈率为38.5倍。
核心要点
- 营收同比变化+12.5%
- 净利润率11.8%
- 市盈率38.5倍
STVN的营收增长为+12.5%，市盈率为38.5倍。
Stevanato Group S.p.A. (STVN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
员工人数
5,795
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.05
股息收益率
0.26%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。